Replagal (agalsidase alfa) / Samaritan Pharma, Takeda  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
2021-002320-20: A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Un estudio para evaluar el efecto de comprimidos de venglustat sobre el índice de masa ventricular izquierda en pacientes hombres y mujeres adultos con enfermedad de Fabry.

Ongoing
3
110
Europe
Venglustat, SAR402671, GZ402671 or GZ/SAR402671, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Capsule, hard, Replagal, Fabrazyme, Galafold
sanofi-aventis recherche et développement, sanofi-aventis recherche et développement
Fabry’s disease Enfermedad de Fabry, Fabry’s disease Enfermedad de Fabry, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04974749: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Completed
3
20
RoW
REPLAGAL, Agalsidase Alfa, TAK-675
Takeda
Fabry Disease
01/24
01/24
2022-004246-35: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Not yet recruiting
3
20
RoW
Replagal, TAK-675, Concentrate for solution for injection/infusion, Replagal
Takeda Development Center Americas, Inc, Takeda Development Center Americas, Inc
Fabry Disease, Fabry Disease, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
CARAT, NCT05280548 / 2021-002320-20: A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Agalsidase alfa, Replagal®, Agalsidase beta (GZ419828), Fabrazyme®, Migalastat, Galafold®
Sanofi, sanofi-aventis recherche et développement
Fabry Disease
12/25
07/27

Download Options